Phase 3 Study of HS-10380 Safety in Schizophrenia Patients Initiated by Jiangsu Hansoh
Jiangsu Hansoh Pharmaceutical Co., Ltd. has initiated a phase 3 open-label study to evaluate the long-term safety of HS-10380 in adult patients with schizophrenia in China.